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Allergen immunotherapy is commonly used in the manage-
ment of allergic diseases and it remains the only specific treat-
ment for hymenoptera venom anaphylaxis. Venom immuno-
therapy (VIT) is recommended for patients with a history of IgE-
mediated severe systemic allergic reactions, including anaphy-
lactic reactions involving respiratory or cardiovascular symp-
toms.
1 The effectiveness of bee venom immunotherapy has 
been well established over the past 30 years and it is considered 
the treatment of choice for systemic allergic reactions induced 
by hymenoptera stings. Several studies have confirmed the ef-
fectiveness of VIT, demonstrating favorable patient responses 
to deliberate or field stings by the culprit insect after achieving 
the maintenance dose.
2 Desensitization by immunotherapy has 
been performed for several allergic situations throughout the 
last century, but its precise mechanism remains obscure. Many 
studies have focused on the roles of lymphocyte subsets in im-
munotherapy, while very few have examined the action of hy-
menoptera venom on basophilic cells directly. The basophil ac-
tivation test (BAT) has not been used to evaluate the basophil 
response to hymenoptera bee venom. Consequently, many im-
munotherapy guidelines are based primarily on accumulated 
clinical experience, rather than on a genuine understanding of 
the cellular mechanism of the desensitization process. Addition-
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ally, some concerns remain about the relative safety of this form 
of therapy. There is some evidence of local allergic reactions as-
sociated with subcutaneous immunotherapy: side effects are 
fairly common and they are more frequent with honey bee VIT 
than with wasp treatment, especially during the maintenance 
phase compared with the increasing-dose phase.
1 Moreover, the 
advantage of using aqueous extracts is unclear, and aqueous 
preparations of honey bee venom have early local side effects, 
compared with depot extracts for VIT.
2 The occurrence of ad-
verse systemic and local reactions in allergen immunotherapy 
remains a major problem for both patients and clinicians.
3 Is it 
possible to investigate the basal mechanism of immunotherapy 
and hymenoptera venom action by studying human basophils 
from control non-atopic subjects? VIT is used mostly for allergic 
symptomatic individuals, although preventive VIT is considered 
for populations at risk, such as beekeepers.
4 Sting-sensitized 
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Apis mellifera L. bee venom is the most studied hymenoptera allergen, but many aspects of its action on human basophils remain unclear. Allergolo-
gists seek evidence of the effectiveness of bee venom immunotherapy as this approach is the chosen treatment for systemic allergic reactions. The 
effect of bee venom on human basophils in vitro has not been studied in detail for many reasons, including the paucity of basophils in peripheral blood, 
inter-individual basophil response variability, and the reliability and predictability of basophil activation tests. We conducted a brief preliminary sur-
vey of the effect of Apis bee venom on healthy asymptomatic (non-allergic) subjects. A dose of an aqueous commercial extract of Apis bee venom 
as high as 10 μg/mL activated resting basophils (CD63=+80-90%, CD203c=+30%), while it inhibited the expression of CD63 (-50%) following baso-
phil stimulation by the soluble agonists formyl-Met-Leu-Phe or anti-IgE. The activation of resting basophils appeared to be dose-related. Only when 
basophils were activated with an IgE-mediated agonist, did bee venom extract exhibit a possible priming mechanism at the lowest doses used only 
via CD63, while it was ineffective via CD203c. Autocrine interleukin-3 may play a role in the observed biphasic behavior.
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subjects can be enrolled from a healthy asymptomatic screened 
population, such as blood donors. For this population, the hon-
ey bee venom used for VIT has effects comparable to those de-
scribed in individuals allergic to insect stings, constituting a good 
model for investigating the biology of VIT.
Subjects were recruited from regular plasma donors, who 
signed informed consent approved by the Ethics Committee. 
All individuals were screened for serum total IgE and subjects 
with abnormal plasma levels were excluded as donors and from 
this study. To assess the effects of hymenoptera immunothera-
py on standard cell function, human basophils from 48 healthy 
screened blood donors (mean age 39.21±6.76 years, 48% female), 
with normal serum total IgE, who were non-atopic, asymptom-
atic, and had not undergone hymenoptera VIT, or any drug ther-
apy in the previous 48 hours, were treated for 10 minutes at 
37°C with an aqueous extract of honey bee (Apis mellifera L.) 
venom (HoBV; Pharmalgen-Alk Abelló, Horsholm, Denmark) 
and then activated with different agonists (N-formyl-L-Met-L-
Leu-L-Phe, Sigma Aldrich, MO, USA or polyclonal goat anti-hu-
man IgE, Invitrogen Life Technologies, Carlsbad, CA, USA) for 
30 minutes, according to published methods.
5 After activation in 
HEPES-buffered medium (pH=7.36) containing 2.5 mM CaCl2 
and 1 mM MgCl2, cell stimulation was stopped with HEPES-
EDTA (2.8 mM) and the basophils were stained with fluoro-
chrome-labeled monoclonal antibodies CD123-PECy5, HLADR-
PECy7, CD45-APC-Cy7 (for cell electronic capture and pheno-
typing), and CD63-FITC and CD203c-PE, as activation markers, 
and then kept for 20 minutes at 4°C. The erythrocytes were then 
lysed with ammonium buffer (pH=7.2), and the basophils were 
resuspended in phosphate-buffered saline solution (pH=7.4) 
and evaluated by flow cytometry, according to published meth-
ods.
5 The flow analysis was performed using a two-laser BD 
FACScanto flow cytometer; this instrument has a 10,000 
events/s capability, six-color detection, and 0.1% sample carry-
over. Analyses were performed with a mean flow rate of 300–
500 events/s, setting an excess limit of 50,000 events to record 
in the basophil gate to evaluate the entire buffered suspension 
volume and properly estimate cell recovery and reproducibili-
ty. Compensation followed the manufacturer’s instruction, ac-
cording to an off-line procedure by applying automated elec-
tronics algorithms and preset templates, using bi-parametric 
logarithmic dot plots, gate-specific tubes and single-tube data 
analysis, and optimizing the forward scatter threshold and flu-
orochrome voltage as set-up parameters. To evaluate non-spe-
cific fluorochrome staining, isotype controls for anti-IgG1 and 
anti-IgG2α were introduced in the preliminary procedure to set 
up the photomultiplier and instrument technical parameters; 
this control used a staining procedure carried out without in-
troducing the fluorochrome of interest to the assay system. The 
mean fluorescence intensity (MFI) for each fluorochrome-la-
beled monoclonal antibody was calculated automatically with 
the cytometer software by averaging the total fluorescence of 
the marker in the basophil gate. In addition, the software calcu-
lated the percentage of activated cells (CD63
expr%) by consider-
ing the CD63-FITC bright cells counted to the right of a thresh-
old that was established including the main peak of fluores-
cence of a sample of resting cells. To reduce the standard devia-
tion due to brightly fluorescent cells versus dimly fluorescent 
ones, a logarithmic scale and the coefficient of variation to 
measure variability dispersion were used. The percent effect of 
the dose-response curves was calculated by referring to 0 μg/
mL HoBV as:
[-100+(mean Nx/mean N0)×100],
where Nx is the indicated values and N0 the reference values. 
Statistics were determined using the Sigma Plot 10.0 software 
and SPSS 18.0 for data analysis, applying the Shapiro-Wilk test 
for normality and a non-parametric Wilcoxon’s signed-rank 
test for data evaluation.
Figure summarizes the results of 12 separate triplicate experi-
ments, expressed as the mean ± SEM, with the P values of sig-
nificant effects (*P<0.05; 
†P<0.01). In resting non-activated ba-
sophils (Figure, plots A-C), HoBV increased the expression of 
both the markers in a dose-dependent fashion. The greatest 
membrane marker up-regulation was at 10 μg/mL HoBV (+99.4
%, P=0.003, +81.8%, P=0.046, and +33.1%, P=0.006 for CD63-
MFI, CD63
expr%, and CD203c-MFI, respectively) compared with 
HoBV non-treated cells. HoBV induced CD63 and CD203c up-
regulation in resting, non-activated basophils and inhibited the 
expression of these molecules on the cell membrane in stimu-
lated basophils at the highest honey bee venom concentration 
used. Agonists were able to down-regulate membrane markers 
expression at 10 μg/mL HoBV. The dose-response trend disap-
peared when basophils were treated with 100 nM N-formyl-L-
Met-L-Leu-L-Phe (fMLP; Figure, plots D-F), but the highest 
HoBV concentration inhibited membrane marker expression 
elicited by bacterial formylated peptides (-67.2%, P=0.0027; 
-33.8%, P=0.033; -38.6%, P=0.035 for CD63-MFI, CD63
expr% and 
CD203c-MFI, respectively). This inhibitory effect was also ob-
served when basophils were triggered with 2.0 μg/mL anti-IgE 
(-53.1%, P=0.020 for CD63-MFI, Figure, plot G; -49.6%, P=0.048 
for CD63
expr%, Figure, plot H; -17.1 P=0.480 for CD203c, Figure, 
plot I). However, lower HoBV concentrations induced in-
creased CD63 expression compared to HoBV non-treated cells 
and the increase was inversely proportional to the HoBV dose, 
reaching up-regulation exceeding 60% (+61.6%, P=0.0224 for 
CD63; +61.5, P=0.0136 for CD63
expr% at 0.01 μg/mL, Figure, plots 
G, H). No such effect was observed for CD203c (Figure, plot I). 
In an IgE-mediated activation pathway, HoBV stimulation was 
superimposed on that of anti-IgE. While the two markers 
showed a similar pattern for non-IgE-mediated activation, they 
behaved quite differently in basophils triggered with anti-IgE.
Activation of the ectoenzyme CD203c by HoBV was previous-
ly described in stung individuals with a diagnosed allergy to 
wasp or bee venom.
6 More recently, this marker was found to Chirumbolo et al.
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be related to the role of interleukin-3 in human basophils, be-
cause the cytokine modulates CD203c membrane expression.
7 
A low level of IgE/FcεRI cross-linking in response to low doses 
of honey bee venom allergens can induce autocrine IL3 activi-
ty, leading to basophil priming.
8 In this study, we showed that 
HoBV induces membrane marker up-regulation from the basal 
level, confirming previous reports.
6,9 When IgE-FcεRI is triggered 
by an allergen, even at low concentration, basophils produce 
and bind the IL-3 they release, thereby inducing a primed state 
and augmenting the IgE-mediated response.
8 In fact, the cyto-
kine can induce priming, but also sustains IgE-mediated acti-
vation.
10 Regular low doses of HoBV induce CD203c up-regula-
tion, a mechanism in which IL-3 may play a role,
8 which in turn 
modulates basophil activation by two mechanisms, one of which 
is IgE- and calcium-dependent.
7,10 CD203c induced by auto-
crine IL-3 is not further up-regulated by the concentration of 
anti-IgE.
7 This concurs with evidence that HoBV increases bas-
al CD203c, but it is not able to increase CD203c up-displace-
ment on the basophil membrane following activation with an-
ti-IgE.
Regarding the tetraspanin CD63, very low doses of HoBV in-
duced synergistic marker up-regulation following stimulation 
with the anti-IgE agonist, while venom concentrations as high 
as 10 μg/mL triggered down-regulation in both activation path-
ways. Previous reports have shown that when IL-3 and anti-IgE 
are combined, the result is additive or supra-additive, depend-
ing on the basophil donor, leading to a clear priming phenom-
enon.
8 This seems to be the case, suggesting that HoBV induces 
autocrine IL-3 in basophils. fMLP cannot induce an increase 
via a synergistic effect on FcεRI, because it does not elicit IL-3 
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Figure.  Dose response curves of honey bee venom (HoBV) on resting non-activated basophils (A-C) or cells stimulated with 100 nM fMLP (D-F) or 2.0 μg/mL anti-
IgE (G-I). Values are expressed as mean±SEM of 12 separate triplicate experiments. See text for statistics.
*P<0.05; 
†P<0.01.
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production,
8 but a high level of HoBV at IgE-FcεRI, which exerts 
an activation response at the basal level, might trigger a down-
regulation pathway, probably involving a signaling pathway.
8 
This evidence supports the hypothesis that high HoBV concen-
trations do not inhibit basophil function via a cytotoxic effect.
This hypothesis needs to be investigated further and our data 
are preliminary evidence. Others have extensively analyzed au-
tocrine IL-3 mRNA levels and cytokine synthesis in basophils 
activated with anti-IgE of fMLP.
8 We were unable to find a better 
interpretation of the reported evidence.
What is the clinical relevance of these findings? Recent reports 
indicate that IL-3 is not essential for local or systemic anaphy-
laxis
11; so our evidence is not directly related to systemic reac-
tions following an insect sting involving an anaphylactic mech-
anism. Our evidence shows only that desensitization is a conse-
quence of HoBV at an activated cellular state. However, the 
mechanism of action we suggest is a hypothesis, and we do not 
know whether this mechanism involves down-regulation me-
diated by IL-3, IgE-receptor internalization, protein tyrosine 
phosphatases, or histamine feedback on H2 receptors; there 
may also be a role for intracellular modulation of the activating 
signal.
12-14 The aqueous HoBV used in immunotherapy appears 
to have biphasic (hormetic) behavior. Low doses of HoBV can 
diffuse into the systemic circulation and induce an activated 
state, while high doses elicit a primed state, but they induce 
IgE-FcεRIβ desensitization, as allergen/IgE cross-linking in-
creases, a mechanism that allows us to suggest that the higher 
the priming is, the greater the desensitization. This occurs in all 
stung subjects, both sensitized asymptomatic and hymenop-
tera allergic subjects, raising issues about VIT maintenance time 
and doses.
4 VIT effectiveness is strictly dependent on allergy 
desensitization mechanisms, and an understanding of this is a 
major goals of immunotherapy. In this regard, many attempts 
to prevent side effects in immunotherapy, from induced cell-
anergy with intracellular inhibitors
15,16 to IgG/FcγRIIb regula-
tion of IgE/FcεRI cross-linking,
16 have been suggested, but their 
clinical feasibility is limited.
17 In this context, the observed bi-
phasic behavior should be assessed further to ameliorate VIT in 
hymenoptera allergy and to gain new insights into the role of 
basophils in allergy inflammation. 
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